Identiv Wins 2021 Security Today IoT New Product of the Year Award
uTrust Sense SyringeCheck honored as Internet of Things winner for delivering smarter, simpler, safer medical outcomes
FREMONT, Calif., Aug. 19, 2021 /PRNewswire/ -- Identiv, Inc. (NASDAQ: INVE), a global leader in digital identification and security, today announced its near field communication (NFC)-enabled injectable dose monitoring device won the 2021 Security Today New Product of the Year Award in the Internet of Things (IoT) category. The annual award program honors the outstanding technological achievements of innovators with products considered valuable in their ability to propel positive business and security outcomes.
Security Today selected Identiv's uTrust Sense SyringeCheck as the winning IoT entry for its ability to help patients take medication correctly. It is the only intelligent injectable technology available today and allows clinical trials to achieve meaningful results and supports insurance companies' prescription programs. It also makes the lives of those receiving and using medication easier and more affordable by permitting in-home injections instead of requiring expensive and time consuming in-clinic visits.
The NFC-enabled syringe dose monitoring device features a front-end capacitive sensor to measure fill levels combined with a companion app and alarm function to guide patients through the correct medication protocol, greatly simplifying the process of complex prescription programs. The solution is highly intuitive thanks to its tap-and-go sensor read-out and is seamlessly compatible with telemedicine and at-home compliance monitoring.
In addition to ensuring patient safety, healthcare providers can leverage uTrust Sense SyringeCheck to conduct trials in the home environment instead of a clinic — a critical benefit with the surge of COVID-19 variants — making the solution lower cost and more convenient. Providers can quickly identify non-compliant participants, exclude them from results, and save money with more efficient studies.
"With the continued, exponential growth of connected devices, there is increased demand for new ways to leverage RFID and NFC in MedTech, helping healthcare providers and patients ensure the safe and secure delivery of medicine," said Identiv COO Dr. Manfred Mueller, Ph.D, Chemistry. "Our intelligent syringe solution is designed to streamline the delivery of prescriptions while verifying individuals are safely taking their medicines as designed. We are honored to play an important role in keeping patients around the world safe, and healthcare and insurance providers more efficient with health management."
Dedicated to delivering secure authentication within the IoT, Identiv's NFC and RFID solutions are proven to be highly effective in the healthcare, pharmaceuticals, and MedTech markets. The portfolio of solutions is deployed at medical facilities and pharmacies worldwide, trusted to provide contactless device identification, verify compliance and processes, protect patient health and safety, reduce costs by reducing the need for clinic visits, and improve compliance with dosage protocols.
Identiv will demo uTrust Sense SyringeCheck in addition to a wide range of MedTech solutions, including temperature tracking technology, vaccine cold chain monitoring, and pharmaceutical devices for the visually impaired, at RFID Journal LIVE! in Phoenix, Ariz., September 26 - 28, 2021. Visit booth #519 or book a demo during the event.
For more information on Identiv's RFID and NFC-enabled devices, call +1 888.809.8880 or contact [email protected].
About Identiv
Identiv, Inc. is a global leader in digitally securing the physical world. Identiv's platform encompasses RFID and NFC, cybersecurity, and the full spectrum of physical access, video, and audio security. Identiv is a publicly traded company, and its common stock is listed on the NASDAQ Stock Market LLC in the U.S. under the symbol "INVE." For more information, visit identiv.com.
Note Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those involving future events and future results that are based on current expectations as well as the current beliefs and assumptions of the Company's management and can be identified by words such as "anticipates", "believes", "plans", "will", "intends", "expects", and similar references to the future. Any statement that is not a historical fact, including statements regarding the Company's expectations regarding future operating and financial outlook and performance, including statements regarding the Company's beliefs with respect to it's the benefits of its recurring revenue model; the Company's beliefs with respect to economic recovery and growth in commercial and retail markets; the Company's beliefs regarding the reasons for customer orders; the Company's beliefs regarding trends and the drivers of such trends; the Company's expectations regarding growth in its Premises segment in the second quarter of 2021; and the Company's beliefs regarding recovery in the commercial verticals driving higher gross margins and expanded EBITDA margins in 2021 and into 2022 is a forward-looking statement. Forward-looking statements are only predictions and are subject to a number of risks and uncertainties, many of which are outside our control, which could cause actual results to differ materially and adversely from those expressed in any forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to the extent and duration of economic recovery and growth in commercial and retail markets, the Company's ability to continue the momentum in its business, its ability to successfully execute its business strategy, its ability to capitalize on trends in its business, the level and timing of customer orders, the success of its products and partnerships, industry trends and seasonality, the impact of COVID-19, and factors discussed in its periodic reports, including its Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent reports filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update such statements.
Investor Relations Contact:
Matt Glover and Sophie Pearson
Gateway Investor Relations
+1 949.574.3860
[email protected]
Media Contact:
[email protected]
SOURCE Identiv
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article